Stock NMRA NEUMORA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Neumora Therapeutics, Inc.

Equities

NMRA

US6409791000

Real-time Estimate Cboe BZX
Other stock markets
 09:45:00 2024-05-22 am EDT 		5-day change 1st Jan Change
9.315 USD -1.43% Intraday chart for Neumora Therapeutics, Inc. -1.60% -44.19%
May. 14 Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression MT
May. 14 Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression
MT
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
AQ
Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
CI
Neumora Therapeutics Shares Fall as Q1 Loss Narrows
MT
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
Neumora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Neumora Therapeutics to Participate in Upcoming Conferences in May
AQ
Sector Update: Health Care Stocks Advance Premarket Monday
MT
Sector Update: Health Care
MT
Investors Shrug Off Geopolitical Concerns, Driving Premarket Gains for US Equity Futures
MT
Upcoming Earnings Buoy Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday
MT
Top Premarket Decliners
MT
Neumora Therapeutics' Phase 1 Trial of Potential Brain Disease Drug on Hold After Convulsions in Rabbits
MT
Neumora Shares Slide Premarket as FDA Puts Early Study of Schizophrenia Drug on Hold
DJ
Neumora's early-stage schizophrenia drug study put on hold
RE
U.S. FDA places clinical hold on Neumora's schizophrenia drug study
RE
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
AQ
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
CI
JPMorgan Adjusts Price Target on Neumora Therapeutics to $22 From $20, Maintains Overweight Rating
MT
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to S&P Global BMI Index
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NMRA Stock
  4. News Neumora Therapeutics, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW